RNAZ - TransCode Therapeutics, Inc. Net Sales Margin

TransCode (RNAZ) - corporate logo

TransCode Therapeutics (RNAZ) is scaling its RNA platform to combat solid tumors through clinical trials. The actual net profit margin reflects current business dynamics, with the metric standing at 0.00. Prospects rely on iron oxide nanoparticles to destroy metastases and the brand's high authority in developing precision genetic tools that deactivate oncogenes.

transcodetherapeutics.com (RNAZ) Net Profit Rate: for the period 07/04/2022 - 11/19/2026

Analytical breakdowns for transcodetherapeutics.com (RNAZ)

- share price and expert price forecast:
Comprehensive company analysis:TransCode, RNAZ
Manufactured product of TransCode Therapeutics

TransCode Therapeutics (RNAZ) operates as an early-stage biotech startup focused on preclinical trials of its DNA platform with no active sales. Under these conditions, the absence of revenue makes the calculation of the net income margin mathematically unstable. This indicator measures the percentage of profit the company retains after deducting all operating and tax expenses. By analyzing the net profit margin, an investor assesses the efficiency of monetizing current assets. The trend of this metric reflects the business's transition from a grant-funded survival stage to commercial realization.

Competitor analysis

TEM: Net Sales Margin|Net Profitability Margin Qiagen QGEN|IONS (Isis Pharmaceuticals) - Net Sales Margin|Repligen Inc. - Net Profit Margin|Net Sales Margin RNA|CRSP - Net Margin|GeneDx - Return on Sales by Net Profit|Net Profit Rate RARE|Beam Tx - Net Sales Margin|SRPT - Net Sales Margin|TWST (Twist Bio) - Return on Sales by Net Profit|Net Return on Sales TXG|Return on Sales by Net Profit NTLA|Stoke Therapeutics Inc (STOK) - Company Sales Margin|Net Sales Margin BLFS|Net Margin WVE (Wave Life Sciences Corp)|Net Margin Maze Therapeutics MAZE|Net Profit Rate SION|PRME - Net Margin|Company Sales Margin Taysha TSHA|QURE: Net Sales Margin|Return on Sales by Net Profit MeiraGTx PLC|RGNX (REGENXBIO Inc) - Net Sales Margin|solidbio.com (SLDB) - Company Sales Margin|Net Margin Ocugen Corp (OCGN)|Pacific Biosciences of California, Inc. - Net Return on Sales|Benitec Biopharma - Return on Sales by Net Profit|DSGN: Net Return on Sales|RCKT: Return on Sales by Net Profit|FDMT - Net Sales Margin|LXEO: Net Sales Margin|Korro Bio Inc. - Net Profit Rate|EDIT (editasmedicine.com) - Net Sales Margin|Net Margin SLN|Net Margin ProQR Therapeutics NV (PRQR)|Codexis - Net Return on Sales|Net Margin Sangamo SGMO|NAUT: Net Return on Sales|MGX: Return on Sales by Net Profit|Net Margin Precision BioSciences|GBIO (generationbio.com) - Return on Sales by Net Profit|Net Margin boundlessbio.com (BOLD)|XCUR (exicuretx.com) - Net Sales Margin|Net Return on Sales IMNN (Imunon, Inc.)|Net Sales Margin PHIO|MBIO - Net Margin|Net Margin Bionano Genomics BNGO|Net Profit Rate APDN|BLUE - Net Margin|Net Profit Margin IPA|Omega Therapeutics, Inc. (OMGA) - Net Margin|Singular Genomics Corp (OMIC) - Net Sales Margin|RGLS (Regulus Therapeutics, Inc.) - Net Sales Margin|SYRS: Net Profit Rate|Return on Sales by Net Profit TBIO (Telesis Bio Inc.)|Net Sales Margin TRACON Pharmaceuticals Inc. (TCON)|Net Margin Unity Bio UBX